		ANZSNM 2019 Posters – Poster Walk 1.15pm – 2.00pm Saturday 27 April
		*GMS Poster Award Nominee
148	P01	Predicting the biodistribution of radioiodide in the setting of renal impairment and dialysis
		Erin Mckay, South Eastern Sydney Local Health District*
106	P02	18F-FDG PET-CT for monitoring treatment response in extra-pulmonary tubercular infections.
		Ajay K Singh, Institute of Nuclear Medicine & Allied Science
108	P03	Language complexity in clinical nuclear medicine Travis Pearson, Metro North HHS*
110	P04	Pictorial review of FDG PET findings in craniofacial giant cell arteritis
		Edward Hsiao, Royal North Shore Hospital
111	P05	Introduction of [18F]F-PSMA-1007 for prostate cancer Imaging at Sir Charles Gairdner Hospital - radiochemist's perspective
		Joseph Ioppolo, Sir Charles Gairdner Hospital
112	P06	Recommendations for the quality control of technetium-99m labelled
		radiopharmaceuticals Daphne James, University of Newcastle
113	P07	Amyloidosis in F18-FDG avid lung nodule
		Madison Bills, Royal Adelaide Hospital- SAMI
120	P08	Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia Rosemary Dallen, Sir Charles Gairdner Hospital
122	Р9	68Ga-DOTATATE expression in breastmilk and the potential dose to the breastfeeding infant
		Judy Duong, Princess Alexandra Hospital*
124	P10	Delivery of 18F-PSMA-1007 through an automatic infusion device
		Simone Culleton, WA PET Service
126	P11	A case of false positive gastrointestinal bleed study from uterine vascular anomaly Mikayla Dimitri, Royal Adelaide Hospital Nuclear Medicine
127	P12	VQ SPECT/CT - To assess the usefulness of routine low dose CT within our department
		Russell Edwards, SA Medical Imaging
129	P13	White cell accumulation in giant cell tumour
		Kim Taubman, St Vincent's Hospital
130	P14	75-seleno-homocholic acid-taurine (SeHCAT) test: A single-centre audit of study
		LIGHT CONTROL OF A CONTROL CON

indications, and the influence of results on management

Karen Fullard, Nuclear Medicine Department

		and three-blood sample methods Catherine Munn, SA Medical Imaging, WCH
135 [P16	A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68Ga-PSMA-11 PET imaging in patients with confirmed prostate cancer Maciej Debowski, Royal Brisbane & Women's Hospital
136 g	P17	Manifestations of scurvy on bone scintigraphy Brianna Powe, Concord Hospital
137	P18	Pachymeningitis demonstrated on Gallium SPECT/CT scan Aaron Rose, Concord Hospital
138	P19	Axillo-femoral graft demonstrated on labelled red and white cell SPECT/CT Brianna Powe, Concord Hospital
140	P20	Patterns of nodal involvement demonstrated on 68Ga-PSMA PET/CT scans for the primary staging of prostate cancer Geoffrey Schembri, Royal North Shore Hospital
141 [P21	Do real-time electronic extremity dosimeters improve staff radiation hygiene and assist in best manual dispensing practice in a busy PET department? Judy Duong, The Princess Alexandra Hospital
144	P22	Spectrum of 123I SPECT/CT Findings in paediatric neuroblastoma in New Zealand. Hayley Wong, Auckland City Hospital
145 F	P23	Immunotherapy-related nephritis in a melanoma patient: a case study Rosemary Dallen, Sir Charles Gairdner Hospital
147	P24	Estimation of radiation dose to sonographers from nuclear medicine and PET patients at a specialist cancer hospital Nicholas Daw, Peter MacCallum Cancer Centre
149	P25	The use of 124 lodine as a diagnostic and theranostic tool for patients with metastatic thyroid cancer Allison Wallace, Royal Brisbane and Women's Hospital*
152	P26	Pulmonary amyloidosis demonstrated on FDG PET/CT, Larry Pijaca, Nepean Hospital
154 բ	P27	Elevated Gallium 68 prostate-specific membrane antigen uptake in colon cancer. Khang Le, Nepean Hospital
157	P28	Sample geometry and its effects on assay results Arlen McDonald, POWH
167	P29	Is Gallium-67 citrate imaging guiding antibiotic therapy for renal transplant patients with urinary tract infections? Remi Hillery, Princess Alexandra Hospital
170	P31	The role of nuclear medicine in the detection of cardiac amyloidosis - a case study Meni (Melpomeni) Rollis, University of South Australia

		Chithradevi Sathiakumar, Liverpool Hospital
189	P43	Radiation monitoring in Liverpool Hospital molecular science cyclotron facility: first year of Operation
188	P42	Galium-68-PSMA-617 as a novel PET-CT marker for disease stratifying metastatic colorectal cancer: A prospective pilot study Tahleesa Cuda, Mater Research Institute - The University of Queensland*
		radioimmunotherapy in mouse models Tahleesa Cuda, Mater Research Institute - The University of Queensland*
187	P41	Theranostics for metastatic colorectal cancer - radioimmunodetection and
186	P40	Arterial FDG uptake - what is normal? Aurora Poon, Austin Health
196	P39	Quantitative analysis of FDG PET/CT for assessment of therapy response in patients with non-small cell lung carcinoma treated with nivolumab Joshua James Morigi, Austin Health
190	P38	Usefulness of radioprotective eyewear in the reduction of occupational dose to the lens of the eye in NM & PET My Linh Diep, Monash Health
185	P37	Titration of 99mTechnetium- macroaggregated albumim doses in lung ventilation/perfusion imaging and its effect on dose reduction Jessica Traczyk, Austin Health
		radiopharmaceutical production Benjamin Nguyen, Austin Health
183	P36	Thien Dinh, Austin Health A simple, robust, fully automated system for dual 68Ge/68Ga generator
182	P35	Preliminary tests on cyclotron production of 68Ga through irradiation of enriched 68Zn powder
		cyclotron Courtney Hollis, South Australian Health and Medical Research Institute
181	P33	Uwe Ackermann, Austin Health* Rapid and automated production of [68Ga]GaCl3 and [68Ga]Ga-DOTA-TATE on a medical
179	P32	Patterns of 18-FDG uptake in differentiating different types of non-malignant diagnoses of mediastinal lymphadenopathy Socrates Angelides, Westmead Hospital Automated radiosynthesis of [177Lu]Lu-PSMA-617 on the iPHASE MultiSyn module
176		Loren Katchel, Princess Alexandra Hospital Queensland Health
174	P31	The application of diagnostic computed tomography in the setting of a clinical PET service - a retrospective analysis

2	202	P45	The Role of FDG and DOTATATE PET in predicting PRRT efficacy: A quantitative lesion-based analysis David Chan, Royal North Shore Hospital
	204	P46	Impact of the bone scan in a complicated Meningococcal patient Emma Harding, Austin Health
2	205	P47	Well-differentiated neuroendocrine neoplasm (NEN) with no or low 68Ga-DOTATATE and 18F-FDG-avidity: an under-recognised molecular imaging phenotype and potential mimicking pitfalls Lamiaa Zidan, Peter MacCallum Cancer Centre*
	206	P48	Initial experience in the clinical utilisation of brain amyloid PET imaging Christian Testa, Austin Health*
	207	P49	Equivocal findings in bone on PSMA PET CT Rueben Ganeshalingam, Royal North Shore Hospital
2	208	P50	Technical feasibility of the measurement of absolute Myocardial Blood Flow (MBF) and Myocardial Flow Reserve (MFR) using novel ultra-low dose dynamic CZT-SPECT technology with 99mTc-Sestamibi and Dipyridamole or Dobutamine Mark Dobson, Bankstown Lidcombe Hospital, South Western Sydney Local Health District*
- 2	210	P51	Methodology for the validation and implementation of new quantitative processing software Vivian Chan, Royal North Shore Hospital
- 2	211	P52	Performing a first in human research trial from the technologist perspective Elizabeth Bailey, Royal North Shore Hospital
	212	P53	The role of a clinical coordinator for the nuclear medicine technologist Elizabeth Bailey, Royal North Shore Hospital
2	214	P54	Artificial intelligence vs human intelligence - quotient analysis on lung VQ scan for diagnosis of pulmonary embolism Michael Nguyen, Austin Health
	215	P55	Optimized F18-Florbetaben Amyloid PET brain reconstruction parameters for qualitative and quantitative review Anita Singh, Royal North Shore Hospital
2	216	P56	PET scanner spatial resolution from contrast phantom measurements Chris Rowe, Austin Health
	217	P57	Dose Calibrator measurements using Copper Inserts Cameron Pain, Austin Health
-	221	P58	Digital Respiratory Gated PET/CT: diagnostic and workflow impact Peter Lin, Liverpool Hospital
7	222	P59	The use of F18 MISO PET-CT to measure serial tumour hypoxia following induction chemotherapy and stereotactic body radiotherapy in locally advanced pancreatic cancer <i>Peter Lin, Liverpool Hospital</i>

227	P60	99mTc heat damaged red blood cell spleen scan detecting thoracic splenosis Bronwyn Jones, Prince of Wales Hospital
160	P61	Labelled red blood cell liver scan in the investigation of suspected haemangioma: A case
		study
		Kate Romeo, University of South Australia*
143	P62	Stability studies of [177Lu]-DOTATATE ([177Lu]-Lutate) for peptide receptor radionuclide
		therapy using carrier added and non-carrier added [177Lu]-Lutetium
		Lyzu Yasmin, Royal North Shore Hospital
121	P63	18F-FDG PET scan in a patient with Refractory DRESS Syndrome
		K Hughes, Royal Adelaide Hospital
159	P64	Standardising the synthesis of [18F]FET (O-(2 [18F] Fluoroethyl)-L-tyrosine) with TET (L-
		Tyrosine, O-(2-tosyloxyethyl)-N-trityl, tert-butyl ester) as the precursor.
		Vijay Kumar, Westmead Hospital & The Children's Hospital at Westmead Australia